Dr. Beljanski was one of the first biologists to study small RNA fragments, which plays an important role in the growth of a cell. Some RNA fragments stimulate the formation of white blood cells and platelets. Mirko Beljanski discovered that they not only help maintain normal white blood cell and platelet levels which may decrease to dangerously low levels in a number of situations, including radiation therapy and chemotherapy, but they also preserve normal proportions among the various kinds of white blood cells, notably those that fight infections. These RNA fragments promote the DNA of healthy cells; never that of cancer cells.
What Beljanski discovered concerning RNA could make chemotherapy or radiotherapy patients rejoice, for they will no longer need to experience its extensive complications or other adverse side effects of these treatments ! That alone makes Beljanski’s discoveries good candidates to be included in the integrative treatments used in forward-thinking cancer hospitals around the world.
Early Research on RNA
Dr. Mirko Beljanski spent the bulk of his professional life devoted not to cancerous DNA but to uncovering the mysteries of RNA. The thirty years he spent at the Pasteur Institute, from 1948 to 1978, were dedicated to some of the earliest discoveries in modern research on RNA and its relationship to DNA.
Beljanski is also arguably the first to have discovered the enzyme “reverse transcriptase”— so-named because it reverses the usual transcription of DNA into RNA. In order for genetic information to be passed from DNA to the rest of the cell and hence to the body as a whole, it has to be transferred from DNA into RNA. Reverse transcription means that RNA is actually transferring genetic information into DNA—the reverse of the usual process. Reverse transcription has become important to all of humanity because of the HIV virus that works exactly on that principle. It is a very complex process, but the simple effect of it is that reverse transcription enables a virus to be inserted into the host’s DNA and replicated by the host and that’s why HIV seems impossible to cure or even treat with any good effect.(2)
In 1974, Dr. Beljanski was definitely the first to detect reverse transcriptase in bacteria. Dr. James Grutsch, clinical-trial consultant to the Cancer Treatment Centers of America, who was a fledgling scientist at the Pasteur Institute during Beljanski’s term there, elegantly explains, “Dr. Beljanski was pioneering research into [RNA] and proving RNA indeed spoke back to DNA and gave it new information that changed its [DNA’s] blueprint.” Dr. Grutsch, nodding to the constant dissention between Beljanski and Monod, adds, “if [Beljanski] survived all those years under a director like Monod—who did not tolerate dummies—he must have been a darn good scientist. He had done all of the work to show us that we could actually save lives with RNA. ”(3)
It is a work-intensive process to procure RNA fragments, but Beljanski proved they could help bone marrow stem cells speed-up the production of both red and white blood cells, and platelets. Just as important, the bacterial RNA fragments did not act on the in vivo brain, lungs, or muscles, nor on leukemia cells. When injected into living animals, these fragments concentrated in the spleen and the bone marrow of the animal.
They found these fragments behave like selective promoters of bone marrow DNA. Bone marrow is where blood cells, both white and red, plus the platelets are manufactured.
Awareness of this activity of RNA fragments is tremendously important for patients undergoing chemotherapy. One of the unwanted side effects of taking cytotoxic chemicals to kill cancer is that it attacks the body’s healthy bone marrow, gastrointestinal tract, and the mouth. As a result of chemotherapy, mucous membranes in the mouth, for instance, split, crack, and cause burning but this can be alleviated or prevented altogether by use of RNA primers.(4)
Platelet Counts are Restored
Chemotherapy can also create a condition known as thrombocytopenia, where the blood platelet counts drop to dangerously low levels. The problem when blood-cell count and/or platelet counts drops too low is that the chemical or radiation treatments must be stopped because the patient could bleed to death during the course of treatment. But stopping treatment leaves the body vulnerable to the cancer cells resuming their constant replication—a condition no cancer patient wants.
While hospitals now regularly use synthetic medicines to help boost the production of white blood cells, until Beljanski’s research was rediscovered, there was nothing natural to help the blood-cell dilemma and nothing at all to help increase platelet counts, except suspending treatment and giving a blood transfusion.
Beljanski and his team found that RNA fragments promoted the quick production of new platelets to replace the platelets destroyed by chemotherapy. More importantly, the repeated doses of these fragments did not lead to tolerance or toxicity among cancer-affected rabbits treated with the antimitotics that are so toxic to healthy cells. Increased dosage was without incidence since the fragments were found to be destroyed within four hours by means the body’s powerful natural regulation. What’s more, they did not block the action of the antimitotics and could be applied with almost any cancer-fighting agent.
After uncovering the restorative effects of RNA fragments in vivo, Beljanski teamed up with several MDs who administered the fragments to people with cancer. The RNA fragments behaved the same in humans as they did in animals protecting patients receiving radiation therapy and intensive chemotherapy. This was a new beneficial discovery which worked well, provided that human patients received enough RNA primers early in their conventional treatments. Beljanski found the primers needed to be administrated before all of the cancer patient’s bone marrow stem cells are destroyed by chemotherapeutic poisons.(5,6,7,8,9,10)
The evidence is clear: RNA fragments, priming only healthy cells, are powerful healing agents. The other rare cases where RNA fragments show no effect against the side-effects of cancer are either when there is a lack of hemoglobin (in red blood cells which number less than 2.5 million) or when there is an excess of ribonuclease in the blood (ribonuclease is an important enzyme that breaks down RNA into smaller components in part to help the body get rid of excess RNA), which may be partially inhibited by the ingestion of magnesium. An excess in ferritin (a mineral component in which iron is linked to a protein) can also slow down RNA fragment activity.
Because Dr. Beljanski’s research on RNA is so extensive, please see A Pioneer in Biomedecine by C.G. Nordau and Monique Beljanski; Extraordinary Healing by L. Stephen Coles, MD, PhD, if you’re interested in acquiring further information.
Several publications published on RNA fragments, which he also called RLB
Nouvelles substances (R.L.B.) actives dans la leucopoïese et la formation des plaquettes. Authors : M. BELJANSKI, M. PLAWECKI, P. BOURGAREL, M. S. BELJANSKI. Bull. Acad. Nat. Med., 1978, 162, Volume n°6, pp. 475-781. Available in French only, Abstract in French and English
Oligoribo-nucleotides, promoters of leucocyte and platelet genesis in animals depleted by anticancer drugs. Authors : M. BELJANSKI NCI-EORTC. Symposium on nature, prevention and treatment of clinical toxicity of anticancer agents. Institut Bordet, Bruxelles, 1980. Article not available online
Short chain RNA fragments as promoters of leucocyte and platelet genesis in animals depleted by anti-cancer drugs. Authors : M. BELJANSKI, M. PLAWECKI, P. BOURGAREL, M.S. BELJANSKI. In the Role of RNA in Development and Reproduction. Sec. Int. Symposium, april 25-30, 1980, pp.79-113. Science Press Beijing. M.C. Niu and H.H. Chuang Eds Van Nostrand Reinhold Company. Article not available online
Comparative study of Escherichia coli endotoxin, hydrocortisone and Beljanski leukocyte restorer activity in cyclophosphamide-treated rabbits. Authors : M. BELJANSKI, PLAWECKI. Proc. of the Soc. for Exp. Biol. and Med., 168, 1981, pp. 408-413. Available in English only
Leucocyte Recovery With Short-Chain RNA Fragments in Cyclophosphamide-Treated Rabbits. Authors : BELJANSKI, M. PLAWECKI, P. BOURGAREL, M.S. BELJANSKI. Cancer Treatment Reports, 67, 1983, pp. 611-619. Document not available online
RNA Fragments (RLB) and Tolerance of Cytostatic Treatments in Hematology: A Preliminary Study about Two Non-Hodgkin Malignant Lymphoma Cases. Authors : DONADIO, R. LORHO, J.E. CAUSSE, T. NAWROCKI, M. BELJANSKI. Deutsche Zeitschrift für Onkologie, 23, 2, 1991, pp. 33-35. Available in French only
Radioprotection of Irradiated Mice – Mechanisms and Synergistic Action of WR-2721 and R.L.B. Authors : M. BELJANSKI. Deutsche Zeitschrift für Onkologie, 23, 6, 1991, pp. 155-159. Available in English only.
You can now find the note of Dr. Marcowith’s protocols on our website.
(1) Extraordinary Healing pg. 41
(2) A Pioneer in Biomedicine, chapter 3
(3) Coles, L. Stephen. “RNA Fragments, Anti-Aging, and Immune Heath” The Doctors’ Prescription for Healthy Living. Sept. 2009
(4) BELJANSKI, M.; BELJANSKI, M. S.; PLAWECKI, M.; MANIGAULT, P. “ARN-fragments, amorceurs nécessaires à la réplication « in vitro » des ADN.” C.R. Acad. Sci., 280:363-366, 1975, (série D).
(5) BELJANSKI, M.; PLAWECKI, M.; BOURGAREL, P.; BELJANSKI, M.S. “Nouvelles substances (R.L.B.) actives dans la leucopoïèse et la formation des plaquettes.” Bull. Acad. Nat. Med., 162(6) :475-781, 1978.
(6) BELJANSKI, M. & PLAWECKI, M. “Particular RNA fragments as promoters of leukocyte and platelet formations in rabbits”. Exp. Cell Biol., 1979, 47, pp. 218-225.
(7) BELJANSKI, M. “Oligoribo-nucleotides, promoters of leucocyte and platelet genesis in animals depleted by anticancer drugs”. NCI-EORTC Symposium on nature, prevention and treatment of clinical toxicity of anticancer agents. Institut Bordet, Bruxelles, 1980.
(8) BELJANSKI, M.; PLAWECKI, M.; BOURGAREL, P.; BELJANSKI, M.S. “Short chain RNA fragments as promoters of leucocyte and platelet genesis in animals depleted by anti-cancer drugs”. In The Role of RNA in Development and Reproduction. Sec. Int. Symposium, M.C. Niu and H.H. Chuang Eds Van Nostrand Reinhold Company. (Beijing: Science Press, April 25-30, 1980), pp.79-113.
(9) PLAWECKI, M. & BELJANSKI, M. “Comparative study of Escherichia coli endotoxin. Hydrocortisone and Beljanski leucocyte restorer activity in cyclophosphamide-treated rabbits.” Proc. of the Soc. for Exp. Biol. and Med., 168: 408-413, 1981.
(10) DONADIO, D.; LORHO, R.; CAUSSE, J.E.; NAWROCKI, T.; BELJANSKI, M. “RNA fragments (RLB) and tolerance of cytostatic treatments in hematology: A preliminary study about two non-Hodgkin malignant lymphoma cases.” Deutsche Zeitschrift für Onkologie, 23(2): 33-35, 1991. (OLD NOTE 39-43)